Abilify Gambling Lawsuits in 2026: Compulsive Behavior Claims Against the Maker
In 2026, the Abilify gambling litigation is essentially over: thousands of lawsuits alleging the antipsychotic caused compulsive gambling and other impulse control disorders settled confidentially in 2019, and the claims fund closed in 2022. This article explains what plaintiffs alleged, what they won, and what options remain today.
Key Facts
- More than 2,800 Abilify lawsuits were filed between 2016 and 2022, alleging the makers failed to warn that aripiprazole could cause compulsive gambling, binge eating, compulsive shopping, and hypersexuality. Source: Drugwatch, May 2026.
- The defendants reached a confidential settlement in 2019 covering the federal MDL and state cases in California and New Jersey; the court closed the claims fund in 2022. Source: Drugwatch, May 2026.
- In December 2016, Bristol-Myers Squibb agreed to pay $19.5 million to resolve consumer protection claims from dozens of states over its marketing of Abilify. Source: multi-state attorneys general settlement, December 2016.
- An Ontario court approved a $14.75 million Canadian class action settlement in December 2024 over claims that Abilify and Abilify Maintena caused compulsive behaviors without adequate warning. Source: Law360 Canada, January 2025.
- In July 2025, a British Columbia court dismissed a CA$1.2 million individual claim, ruling the plaintiff had not proven Abilify caused her compulsive gambling and shopping. Source: Casino.org, July 2025.
What Plaintiffs Alleged Against the Makers
The lawsuits centered on aripiprazole, the active ingredient in Abilify, prescribed for schizophrenia, bipolar disorder, and as an add-on treatment for depression. Plaintiffs said that after starting the drug, people with no history of gambling began visiting casinos compulsively, sometimes losing life savings.
The core claim was failure to warn. Plaintiffs argued that Bristol-Myers Squibb, which held U.S. distribution rights, and Otsuka Pharmaceutical, the drug's developer, knew from case reports and internal data that aripiprazole could trigger impulse control disorders, yet U.S. labeling did not warn patients or doctors for years. The FDA added a compulsive-behavior warning to Abilify's labeling in 2016, which plaintiffs said came too slowly.
The FDA Warning That Changed the Case
Regulators played a decisive role. The FDA's safety communication warned that aripiprazole could cause intense urges to gamble, eat, shop, or engage in sexual activity in rare cases, and that patients and families often missed the connection. The agency advised prescribers to ask patients about new or increasing urges.
An analysis of the European Medicines Agency's adverse event database found Abilify users reported impulse control problems more often than expected, with a particularly elevated signal for the long-acting injectable form, Abilify Maintena. Similar regulatory-warning dynamics appear in other drug litigations, such as the FDA communications behind the Tylenol autism warning lawsuits.
Where the Litigation Stands in 2026
The U.S. chapter is closed. The 2019 confidential settlement resolved the federal MDL and the coordinated state cases, a claims administrator processed the eligible claims, and the court closed the fund in 2022. As of 2026, attorneys are no longer accepting Abilify cases.
The only recent activity has been outside the U.S. and in individual cases. The Ontario class action settled for $14.75 million with court approval in December 2024. In contrast, the July 2025 British Columbia decision shows how hard individual cases remain: the judge accepted that the plaintiff sincerely believed Abilify caused her behavior but ruled she had not proven causation. Watch explainer videos about mass tort settlement processes on Problem Solved on YouTube.
What Plaintiffs Had to Prove
The British Columbia ruling illustrates the central difficulty: causation. It was not enough to show a plaintiff took Abilify and also gambled compulsively. Courts required evidence that the drug, more likely than not, caused the behavior, typically through expert testimony on timing, dose, and improvement after stopping the drug.
This evidentiary bar is why the MDL settlement, rather than jury verdicts, resolved the docket. Successful plaintiffs generally needed medical records documenting the prescription, contemporaneous evidence of the compulsive behavior such as gambling losses, and physician records noting the behavior's onset after starting the drug. The same documentation discipline matters in other pharmaceutical injury claims, including litigation over antipsychotic metabolic side effects.
Who Benefits From This — and Who Does Not
People currently taking aripiprazole benefit from the warning. The labeling now discloses the impulse control risk, so patients and families can watch for warning signs.
Families of patients who suffered gambling losses. Although the U.S. claims fund is closed, the related brain injury claims guide explains how documented medical evidence supports injury cases.
Canadian class members in the Ontario settlement. People covered by the Kirsch settlement approved in December 2024 benefit from the $14.75 million fund.
Patients who never took the drug, or whose compulsive behavior clearly predated it, do not benefit. The litigation was specific to aripiprazole and to behaviors that began after starting it.
Anyone expecting to file a new U.S. lawsuit in 2026 does not benefit. The MDL is resolved, the fund is closed, and firms are not accepting these cases.
People seeking medical advice do not benefit from litigation summaries. This history cannot tell anyone whether to start, stop, or change a prescription; those decisions belong with the prescribing doctor.
This article provides general information only and is not legal advice. Laws and procedures vary by state and change over time; consult a qualified attorney about your situation.
Frequently Asked Questions
Who benefits from understanding the Abilify litigation today
Current aripiprazole patients and their families benefit most, because the case history explains why the impulse control warning exists and what early signs to watch for. Canadian class members in the Ontario settlement also benefit directly from the $14.75 million fund.
Who is not eligible for compensation from the Abilify settlements
Anyone who did not participate in the U.S. claims process before the fund closed in 2022 is not eligible. People whose gambling or compulsive behavior predated their Abilify prescription, or who never took aripiprazole, were never eligible.
How do I start if I believe Abilify caused compulsive behavior
First, speak with your prescribing doctor before any medication change, since stopping abruptly can be dangerous. Second, document prescription records, dates the behavior began, financial records of losses, and notes from family or physicians. Third, consult a pharmaceutical injury attorney promptly about your state deadline, though firms are generally not accepting new Abilify cases in 2026.
What did the FDA say about Abilify and compulsive gambling
The FDA warned that aripiprazole can cause intense, hard-to-control urges to gamble, binge eat, shop, or engage in sexual activity in rare cases. The agency advised prescribers to ask patients about new or increasing urges and to consider lowering the dose.
Is anyone still accepting new Abilify lawsuits in 2026
No. As of 2026, mass tort firms are no longer accepting Abilify impulse control cases; the federal MDL settled in 2019 and the claims fund closed in 2022.